Italy’s competition authority, the AGCM, has opened an investigation into allegations that Samsung Bioepis, Biogen, Genentech and Novartis entered into an agreement to delay the Italian launch of Samsung/Biogen's Byooviz, a biosimilar version of Lucentis (ranibizumab), Genentech/Novartis's drug for wet age-related macular degeneration.
Officials from the AGCM have carried out inspections at the premises of Biogen Italia and Novartis Farma, while also looking...





